Table 5.
Active combinatorial trials in lung cancer.
| Trial ID | Cancer | PARP inhibitor | Immunotherapy | Phase |
|---|---|---|---|---|
| NCT02484404 | SCLC | Olaparib | Atezolizumab (PD-L1) cediranib (VEGFR) | I/II |
| NCT02660034 | Extensive SCLC | BGB-290 | BGB-A317 (PD-1) | I/II |
| NCT02944396 | NSCLC | Veliparib | Nivolumab (PD-1) + Platinum therapy | I/II |
| NCT02734004 | SCLC | Olaparib | Durvalumab (PD-L1) +/- bevacizumab | I/II |
| NCT03330405 | NSCLC | Talazoparib | Avelumab (PD-1) | II |
| NCT03308942 | NSCLC | Niraparib | Anti-PD-1 | II |
| NCT03775486 | NSCLC | Olaparib | Durvalumab (PD-L1) | II |
SCLC, small-cell lung cancer; NSCLC, non-small-cell lung cancer.